Presentations as the European Cardiology Society meeting taking place in Stockholm, Sweden, showed encouraging late-stage results for two drug candidates that could replace warfarin and aspirin in the prevention of blood clots and stroke and vie for a stake in a global market sector estimated to be worth around $20 billion a year.
Date were revealed on US drug major Bristol-Myers Squibb's (NYSE: BMY) and behemoth Pfizer's (NYSE: PFE) apixaban - showing the drug reduced the rate of stroke by 52% compared with aspirin - and Germany's Bayer (BAY; DE) and USA-based partner Johnson & Johnson's (NYSE: JNJ) Xarelto (rivaroxaban) ' which showed similar efficacy and safety compared to standard therapy, Sanofi-Aventis' Lovenox (enoxaparin) plus warfarin, for the prevention of recurrent venous thromboembolism (VTE) in patients with deep vein thrombosis (DVT).
The Phase III EINSTEIN-DVT clinical trial of the oral anticoagulant rivaroxaban demonstrated non-inferiority compared to the standard of care for the prevention of recurrent venous thromboembolism (VTE) in patients with acute symptomatic deep vein thrombosis (DVT), with a comparable safety profile.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze